37.39
-0.25 (-0.66%)
| Previous Close | 37.64 |
| Open | 37.76 |
| Volume | 391,533 |
| Avg. Volume (3M) | 708,422 |
| Market Cap | 1,890,962,688 |
| Price / Earnings (TTM) | 143.81 |
| Price / Earnings (Forward) | 121.95 |
| Price / Sales | 7.41 |
| Price / Book | 5.69 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 1.25% |
| Operating Margin (TTM) | -24.32% |
| Diluted EPS (TTM) | 0.050 |
| Quarterly Revenue Growth (YOY) | 2.60% |
| Quarterly Earnings Growth (YOY) | 52.40% |
| Total Debt/Equity (MRQ) | 33.72% |
| Current Ratio (MRQ) | 5.01 |
| Operating Cash Flow (TTM) | 57.56 M |
| Levered Free Cash Flow (TTM) | -22.77 M |
| Return on Assets (TTM) | -0.45% |
| Return on Equity (TTM) | 1.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vericel Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -2.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | -0.50 |
|
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 107.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Congress Asset Management Co | 30 Sep 2025 | 1,494,607 |
| 52 Weeks Range | ||
| Median | 50.00 (33.73%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 10 Nov 2025 | 50.00 (33.73%) | Buy | 38.99 |
| 15 Oct 2025 | 41.00 (9.65%) | Buy | 33.59 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HOPPER JONATHAN MARK | - | 37.65 | -1,652 | -62,198 |
| WOTTON PAUL K | - | 37.52 | -5,000 | -187,600 |
| Aggregate Net Quantity | -6,652 | |||
| Aggregate Net Value ($) | -249,798 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 37.56 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WOTTON PAUL K | Director | 03 Dec 2025 | Sell (-) | 2,500 | 37.39 | 93,475 |
| WOTTON PAUL K | Director | 02 Dec 2025 | Sell (-) | 2,500 | 37.65 | 94,125 |
| HOPPER JONATHAN MARK | Officer | 02 Dec 2025 | Automatic sell (-) | 1,652 | 37.65 | 62,198 |
| HOPPER JONATHAN MARK | Officer | 02 Dec 2025 | Option execute | 1,652 | - | - |
| Date | Type | Details |
|---|---|---|
| 14 Nov 2025 | Announcement | Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025 |
| 06 Nov 2025 | Announcement | Vericel Reports Third Quarter 2025 Financial Results |
| 23 Oct 2025 | Announcement | Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |